Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Predict S.P.A. Class B ( (IT:PRE) ) has shared an update.
Predict S.p.A. has secured a tender to supply two Mistral Samplers to the Giovanni Paolo II Cancer Institute in Bari, valued at 79,000 Euros. This award is part of the E.C.C.O. project, which aims to develop non-invasive diagnostic methodologies for colorectal cancer. The project highlights Predict’s leadership in breath analysis technology, potentially enhancing patient comfort and safety while supporting innovative medical research.
The most recent analyst rating on (IT:PRE) stock is a Buy with a EUR1.45 price target. To see the full list of analyst forecasts on Predict S.P.A. Class B stock, see the IT:PRE Stock Forecast page.
More about Predict S.P.A. Class B
Predict S.p.A., founded in 2008 in Bari, is an innovative SME in the healthcare sector, focusing on in vivo diagnostics, breath analysis, and digital healthcare solutions. The company operates through four Strategic Business Units, offering technologies such as Mistral for non-invasive oncological disease screening, Aphel for AI-driven hospital support, and Optip for remote medical consultation.
Average Trading Volume: 30,412
Technical Sentiment Signal: Strong Buy
See more insights into PRE stock on TipRanks’ Stock Analysis page.